Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Entereg Documents Offer Detailed Insight Into REMS Review Process

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

GlaxoSmithKline's urgent communication during Entereg's second review cycle set into motion a process to resolve safety concerns that would eventually manifest in one of the strongest Risk Evaluation and Mitigation Strategy programs to date.

You may also be interested in...

Cholesterol Endpoints Draw Scrutiny At HoFH Panels

The Metabolic and Endocrinologic Advisory Committee accepts LDL lowering as endpoint for homozygous hypercholesterolemia drugs, backing approval of Aegerion’s lomitapide by 13-2 and Genzyme’s mipomersen by 9-6, but hones in on the need for better surrogates for cardiovascular morbidity and mortality.

Adolor Abandons Entereg Chronic OBD Indication, Faces Other Setbacks

Adolor is abandoning development of Entereg (alvimopan) for chronic opioid bowel dysfunction just three months after its post-operative ileus partner, GlaxoSmithKline, returned rights for chronic indications

Adolor Seeks New Entereg Partner; Asks FDA To Weigh In On Chronic Use

GSK returns rights to alvimopan in outpatient settings; partnership continues for approved hospital use.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts